Last Patient Has Completed AlzeCure's Phase Ib Clinical Study with NeuroRestore ACD856

Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856

AlzeCure Pharma AB (publ), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the last patient’s last visit (LPLV) has now occurred in the ongoing Phase Ib clinical trial of ACD856, the lead drug candidate within the NeuroRestore platform, which is being developed for Alzheimer’s disease and other indications.

Last Patient Has Completed AlzeCure’s Phase Ib Clinical Study with NeuroRestore ACD856

AlzeCure Pharma AB announced that the last patient’s last visit has now occurred in the ongoing Phase Ib clinical trial of ACD856, the lead drug candidate within the NeuroRestore platform, which is being developed for Alzheimer’s disease and other indications. [AlzeCure Pharma AB] Press Release